The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Subscribe To Our Newsletter & Stay Updated
